PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.
Eligibility criteria
Qualifiers
Signed, informed consent
Age 18 or more years
Histologically confirmed, SCLC, (newly diagnosed or recurrent); small cell carcinoma of unknown or non-lung origin; or other types of neuroendocrine tumor OR Histologically confirmed prostate cancer, with suspected or confirmed NEPC based upon clinical assays obtained prior to the trial OR Histologically confirmed or suspected primary brain neoplasm OR Desmoplastic small round cell tumors, osteosarcoma, Ewing's sarcoma, rabdomyosarcoma, Wilms tumors, hepatoblastomas, rhabdoid tumors and neuroblastoma patients
At least one tumor lesion on CT2 or MRI ≥ 0.8 cm OR
Disqualifiers
History of anaphylactic reaction to humanized or human antibodies
Pregnant or breast feeding
Psychiatric illness that would interfere with compliance with the study procedures
Inability to undergo PET scan due to weight limit
Trial design
Treatments tested in this trial
- 89Zr-DFO-SC16.56
- SC16.56, Phase I, Cohort 2
- SC16.56, Phase I, Cohort 3
- SC16.56, Phase II
Treatment groups
53 Participants
are divided into 2 treatment groupsLocations
1Memorial Sloan Kettering Cancer Center10065, New YorkNew York, United States
Sponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Source ClinicalTrials.gov